Phase III trial of Sci-B-Vac

Trial Profile

Phase III trial of Sci-B-Vac

Planning
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Hepatitis B vaccine recombinant (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 30 Aug 2017 According to a VBI Vaccines media release, the company expects to initiate in the second half of 2017 in the U.S., Europe and Canada.
    • 30 Aug 2017 According to a VBI Vaccines media release, The company had received a No Objection Letter (NOL) from Health Canada in response to its Clinical Trial Application (CTA) as well.
    • 30 Aug 2017 According to a VBI Vaccines media release, the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for a Phase 3 clinical program evaluating Sci-B-Vac, VBI's third-generation hepatitis B vaccine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top